Puzzle out the regulation mechanism of PI4KIIα activity by Fei Sun et al.
SCIENCE CHINA 
Life Sciences 
© The Author(s) 2014. This article is published with open access at link.springer.com life.scichina.com   link.springer.com 
                  
*Corresponding author (email: changchen@moon.ibp.ac.cn) 
• INSIGHT • June 2014  Vol.57  No.6: 636–638 
 doi: 10.1007/s11427-014-4656-8  
Puzzle out the regulation mechanism of PI4KII activity 
SUN Fei, LI JiangMei & CHEN Chang* 
National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China 
Received April 10, 2014; accepted April 14, 2014; published online April 17, 2014 
 
Citation:  Sun F, Li JM, Chen C. Puzzle out the regulation mechanism of PI4KIIα activity. Sci China Life Sci, 2014, 57: 636–638, 




Phosphatidylinositol 4-kinase II (PI4KII), the most 
abundant PI4K in mammalian cells, is best known for its 
essential role in providing the substrate for phosphatidylin-
ositol 3-kinase (PI3K), an important kinase for phospholipid 
signaling. PI4KII also plays important roles in membrane 
trafficking, phagocytosis and the exo-endocytic cycle of 
synaptic vesicles. Its dysfunction results in tumor growth, 
spastic paraplegia and Gaucher’s disease. Therefore, 
PI4KII may potentially be an important drug target.  
The PI4K family comprises type II (55 kD PI4KII and 
PI4KIIβ) and type III PI4Ks (230 kD PI4KIIIand 92 kD 
PI4KIIIβ). Phylogenetic analysis [1] based on their se-
quences (Figure 1A) reveals that PI4KIIIs are closed to 
PI3Ks thus belong to the PI 3/4-kinase family while PI4KIIs 
have more closed relationship with protein kinases (e.g., 
Actin fragmin kinase). This suggests that PI4KIIs should 
have a substrate binding pocket that is distinct from that of 
PI3Ks and PI4KIIIs. In addition, PI4KII contains a 
‘-CCPCC-’ motif that is palmitoylated in vivo and such 
palmitoylation is important for the kinase activity of 
PI4KII. Thus currently structural information available on 
PI3Ks and the well-developed specific PI3K inhibitors are 
not helpful for understanding the substrate binding specific-
ity and the activity regulation of PI4KIIs. 
Recently, the first crystal structure in the PI4K family, 
the catalytic domain of human PI4KII in an ADP-bound 
form was solved [2], and three novel insertions of PI4KII, 
namely I1 (a palmitoylation insertion), I2 (an RK-rich inser-
tion) and I3 were found in this crystal structure (Figure 1B). 
These three insertions distinguish PI4KII from the struc-
tures of PI3Ks (Figure 1C). Furthermore, a distinct nucleo-
tide-binding pocket of PI4KII differs notably from that of 
PI3Ks, which well explained the insensitivity of PI4KII to 
PI3Ks’ inhibitors. Although many crystal structures of PIKs 
have already been solved, the precise nature of the substrate 
binding pocket is still not clear. The molecular dynamics 
(MD) simulation approach was utilized to identify a putative 
PI-binding pocket that was further evaluated using mutagene-
sis. More importantly, the MD simulation, biochemical and 
mutagenesis studies revealed a novel mechanism for the reg-
ulation of PI4KII’s kinase activity, in which any perturba-
tion of the interaction between PI4KII and the membrane 
will affect either the nucleotide binding or PI binding and 
subsequently modulate the kinase activity of PI4KII. 
Current work [2] has provided insight into how the ki-
nase activity of PI4KII is regulated at the molecular level. 
It also lays a foundation for designing specific PI4KII in-
hibitors and activators for future therapeutic applications. 
Importantly, it brings PI4KII out of the shadow of PI3K 
and sheds new light on the study of PI4KII in its own rite. 
Future studies could be focused on the following directions: 
(i) Discovery of specific inhibitors based on the ADP bind-
ing pocket of PI4KII PI4KII has been proved as an on-
coprotein and suppression of its expression level inhibits 
tumor growth [3]. Recently it was found that dual inhibition 
of EGFR at the protein and activity level via combinatorial 
blocking of PI4KII had a marked anti-tumor effect [4]. 
Thus PI4KII is undoubtedly an effective anti-tumor target. 
A subtype-specific inhibitor of PI4KII is important to 
avoid affecting activities of other PI4K/PI3K family mem-
bers. (ii) Structural studies of the PI-bound form of 
PI4KII Up to now most kinase inhibitors have been de- 
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Figure 1  Structures of phosphatidylinositol kinases and phylogenetic analysis. A, Phylogenetic analysis of phosphatidylinositol kinases and protein kinases 
based on their amino acid sequences. The similarity of each pair of sequences is labeled accordingly. GenBank accession numbers for the amino acid se-
quences of these proteins are NP_060895 for human PI4KII, NP_060793 for human PI4KIIβ, NP_002641 for human PI4KIII, NP_002642.1 for human 
PI4KIIIβ, NP_006209 for human PI3K (p110), AAB29081 for human PI3Kβ (p110β), NP_001269356 for human PI3Kγ (p110γ), NP_005017 for hu-
man PI3Kδ (p110δ), 1CJA_B for actin fragmin kinase, 4KQB_B for the Golgi casein kinase and 3AKK_D for a Helicobacter pylori proinflammatory kinase. 
The later three ones belong to protein kinases. The phylogenetic tree was produced by using the server “Phylogeny.fr” (http://www.phylogeny.fr) [1]. B, 
Crystal structure of the catalytic domain of human PI4KII in ADP bound form (PDB code 4HNE). The N-lobe and C-lobe are colored in blue and green, 
respectively. The palmitoylation insertion I1 and RK-rich insertion I2 are colored in red and gold, respectively. ADP is shown in a sphere model. C, Com-
parison of the structures of PI4KII and PI3K (PDB code 2RD0). The crystal structure of PI3K is shown as cartoon diagrams with the structure of 
PI4KII catalytic domain (colored in golden) superimposed. The views take the same angle in (B). The N- and C-lobes of the catalytic domain are colored in 
blue and green, respectively.
signed based on their ATP binding pocket [5]. There is no 
inhibitor available to block the binding of phospholipids due 
to lack of the phospholipid bound complex structures. 
However, considering that ATP is used widely by many 
kinds of proteins in various physiological pathways. The 
inhibitors to block the binding of ATP could not be easily 
specific and avoid side effects. Thus the ideal inhibitors of 
phospholipid kinases would be designed base on the phos-
pholipid-binding pocket. While a putative PI-binding pocket 
of PI4KII has been discovered via molecular dynamics 
analysis [2], more experimental structural work (crystallog-
raphy, NMR and EPR) should be performed to define pre-
cisely the interactions between PI4KII and PI, which is 
important to develop the specific inhibitors of blocking the 
binding of PI. (iii) Study compounds that can regulate the 
activity of PI4KIIvia tuning the fluctuation of membrane. 
Although the current work [2] has shown that cholesterol 
can regulate the kinase activity of PI4KIIvia non-direct 
interactions, more quantitative investigations are needed to 
precisely define how the activity of PI4KII is regulated via 
the changes of the membrane physical properties. It is also 
valuable to develop other compounds that can increase or 
decrease the physical fluctuation and fluidity of membrane 
and study how these new compounds affect the kinase ac-
tivity of PI4KII. These compounds could be potentially 
useful for anti-tumor and the therapy of neurodegeneration 
diseases. (iv) Study the molecular mechanism of 
PI4KIIpalmitoylation. Although the enzyme for the pal-
mitoylation of PI4KIIhas been proposed, its detailed mo-
lecular mechanism and how the palmitoylation of 
PI4KIIis regulated are still awaiting to be solved.  
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